RBC Capital raised the firm’s price target on Incyte (INCY) to $81 from $72 and keeps a Sector Perform rating on the shares. The company’s ‘989 CALR – Calreticulin – antibody update at ASH “could show potential”, and with longer ET, essential thrombocythemia, follow-up, RBC will look for sustained responses and deepening VAF, variant allele frequency, over time, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte appoints Dave Gardner chief strategy officer
- Incyte price target raised to $115 from $110 at Stifel
- Incyte’s Growth Potential Boosted by Opzelura Approval and Strategic Focus on Myeloproliferative Neoplasms
- Incyte announces additional FDA approval of Opzelura
- Incyte’s Povorcitinib Shows Promise but Faces Competitive Challenges: Hold Rating Maintained